Riccardo Autorino, MD, PhD, FEBU

Riccardo Autorino, MD, PhD, FEBU

Virginia Commonwealth University

Richmond, Virginia

Dr. Autorino is an Associate Professor of Urology at Virginia Commonwealth University in Richmond. After graduating cum laude from Federico II Medical School in Napoli, Italy, Dr. Autorino completed his residency training in the same city, where he also obtained a PhD in Urological Sciences. In 2010, Dr. Autorino moved to the USA, where he first completed a two-year Research Fellowship in Urology, and then a two-year Clinical Fellowship in Advanced Laparoscopic & Robotic Surgery at the Glickman Urological Institute at the Cleveland Clinic in Cleveland, Ohio. In 2012, he was awarded with the Italian Matula Award by the Italian Society of Urology. In 2017, he was recipient of the Hans Marberger Award at the annual EAU meeting. Dr. Autorino serves as reviewer for numerous journals, and he serves as editorial board member of European Urology, World Journal of Urology, Archivos Espanoles de Urologia, and the International Brazilian Journal of Urology. He is the Associate Editor for the Laparoscopy and Robotics section of Minerva Urologica e Nefrologica. He has co-authored over 300 peer-reviewed publications and several book chapters. His main clinical interest is the minimally-invasive treatment of urologic cancers and benign urologic diseases by using robotic-assisted surgery.


Talks by Riccardo Autorino, MD, PhD, FEBU

AUA/ASTRO/SUO Guidelines on Clinically Localized Prostate Cancer

Riccardo Autorino, MD, PhD, FEBU, summarizes the American Urological Association (AUA), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) guidelines on clinically localized prostate cancer. Specifically, he highlights recommendations on shared decision making, risk stratification to dictate the therapy, care options, active surveillance, and directions for future research.

Read More

Cytoreductive Surgery in the Era of Targeted Therapy for Kidney Cancer: If Yes, When?

Riccardo Autorino MD, PhD, FEBU, discusses the decline in using cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) due to the shift toward targeted therapy in urological practice. He explains the rationale behind CN, its drawbacks, and individual scenarios in which it could provide a benefit, as opposed to targeted therapy and nephron-sparing surgery (NSS). Furthermore, he presents the current therapeutic algorithm for patient selection in these treatment options.

Read More

Join the GRU Community

- Why Join? -